Browse the evidence

Dual and poly-agonists (e.g., Tirzepatide) targeting multiple receptors (GLP-1R, GIPR) provide superior weight loss compared to single-agonist GLP-1 therapies.

Dual-agonist drugs like Tirzepatide target both GLP-1 and GIP receptors, offering greater weight loss (up to 21%) than single-agonist GLP-1 drugs. This approach leverages multiple hormonal pathways for enhanced efficacy. It is a once-weekly injection suitable for those who need more potent weight loss support.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (15-23%) and should be considered for patients with higher weight-loss goals or specific comorbidities like MASH or severe OSA.

If you have obesity and related health issues like sleep apnea or fatty liver, your doctor might recommend injectable medications like semaglutide or tirzepatide. These can lead to significant weight loss (15-23%) when combined with lifestyle changes. Discuss the pros and cons of injectable vs. oral options with your provider.

Discontinuation of obesity medications leads to weight regain and reversal of cardiometabolic improvements, necessitating long-term treatment.

If you are taking obesity medications, you likely need to continue them long-term to maintain weight loss. Stopping the medication often leads to weight regain. Talk to your doctor about managing costs and side effects to stay on treatment.

Exogenous GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss (up to 25% of body weight) and improve glycemic control in type 2 diabetes by mimicking the endogenous 'ileal brake' mechanism, primarily through central nervous system appetite suppression and delayed gastric emptying.

GLP-1 receptor agonists are highly effective treatments for obesity and type 2 diabetes, capable of producing weight loss comparable to bariatric surgery. They work by leveraging the body's own hormonal pathways (specifically GLP-1) to reduce appetite and improve blood sugar control. While natural GLP-1 is short-lived and ineffective as a therapy, stabilized analogs overcome this. Patients should expect potential initial gastrointestinal side effects, which are managed by starting with low doses and increasing slowly.

Semaglutide 2.4 mg weekly produces a sustained, slowly decaying weight loss effect in adults with obesity, with an estimated 14.9% reduction in body weight over 68 weeks compared to placebo.

Take 2.4 mg of semaglutide once weekly as part of a lifestyle intervention. Expect significant weight loss (around 15% over 68 weeks) compared to placebo. Adherence is key, as discontinuation reduces effectiveness.

Once-weekly subcutaneous semaglutide 2.4 mg significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in patients with obesity or overweight with comorbidities, with effects driven by both improvements in the treatment group and declines in the placebo group.

If you have obesity or overweight with related health issues, taking semaglutide 2.4 mg once a week along with lifestyle changes can significantly improve how you feel about your health compared to doing nothing. This improvement is seen in both those who take the drug and those who don't, as the drug helps maintain health while the placebo group's health utility tends to drop. The benefits include better physical functioning and overall quality of life.

Semaglutide (2.4 mg) and Tirzepatide (15 mg) produce significantly greater weight loss (14.9% and 20.9% respectively) in non-diabetic obesity compared to current approved drugs, though they are associated with frequent gastrointestinal adverse events.

If you have obesity without diabetes, newer injectable medications like semaglutide or tirzepatide are currently the most effective pharmacological options, capable of reducing body weight by 15-21%. However, you must be prepared for gastrointestinal side effects like nausea and diarrhea, which are common but often manageable with gradual dose increases.

Pharmacotherapy using GLP-1 receptor agonists (semaglutide) or dual GIP/GLP-1 agonists (tirzepatide) produces significant weight loss (10-20%) and improves obesity-related comorbidities, serving as a necessary adjunct to lifestyle intervention for patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with complications.

If you have a BMI over 30 (or over 27 with health issues like high blood pressure or diabetes), lifestyle changes alone often aren't enough because your body fights weight loss. Medications like semaglutide or tirzepatide, taken once weekly, can help you lose 10-20% of your body weight and improve your health conditions. These are long-term treatments; stopping them usually leads to regaining the weight. If cost is a barrier, ask your doctor about starting at a lower dose, which may still be effective.

Discontinuation of obesity pharmacotherapy leads to significant weight regain and recurrence of metabolic benefits loss, necessitating lifelong treatment or intensive lifestyle support.

Obesity is a chronic condition, much like high blood pressure. If you stop your medication, you will likely regain the weight and your health markers (like blood sugar and blood pressure) may worsen. Most people need to stay on treatment long-term to maintain their health benefits. If you want to stop, discuss a plan with your doctor, as weight regain is very common.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to selective GLP-1 receptor agonists by improving beta-cell function, enhancing insulin sensitivity independent of weight loss, and modulating central appetite regulation.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective for lowering blood sugar and reducing body weight, often outperforming older GLP-1 drugs. It improves insulin sensitivity directly, not just through weight loss. Common side effects like nausea may be less severe due to the GIP component. It is prescribed for Type 2 Diabetes and Obesity.

Protein supplementation augments strength and hypertrophy.

If you are doing resistance training, protein supplementation can help you build more strength and muscle.

Creatine supplementation augments strength.

Creatine supplementation is an effective way to increase strength when combined with resistance training.

Adherence to a Mediterranean diet supplemented with extra-virgin olive oil or nuts significantly reduces cardiovascular events and inflammatory biomarkers compared to a low-fat diet.

Adopt a Mediterranean dietary pattern, specifically ensuring the inclusion of extra-virgin olive oil or nuts. This approach has been shown to reduce cardiovascular events and inflammation more effectively than a standard low-fat diet in high-risk individuals.

High-dose semaglutide (2.4 mg once weekly) significantly reduces the risk of major adverse cardiovascular events in overweight or obese adults without diabetes who have pre-existing cardiovascular disease.

If you are overweight or obese and have existing heart disease (like a prior heart attack or stroke) but do not have diabetes, high-dose semaglutide (2.4 mg weekly) is a clinically proven intervention to significantly lower your risk of future cardiovascular events, including heart attack and stroke. This benefit is independent of diabetes status and is achieved through a once-weekly injection alongside standard heart medications.

Oral GLP-1 receptor agonists (orforglipron and oral semaglutide) produce clinically meaningful double-digit weight loss (11.2–13.6%) and cardiometabolic improvements in adults with obesity without diabetes, offering a viable alternative to injectable therapies.

Oral GLP-1 medications like orforglipron and oral semaglutide are now proven to help adults with obesity lose significant weight (11-13%) and improve heart health markers without needing injections. If you struggle with needles or prefer a pill, these are viable, effective options, though you should discuss specific dosing rules and potential side effects like nausea with your doctor.

Adherence to the DASH dietary pattern reduces systolic blood pressure by 1–13 mm Hg and diastolic blood pressure by 1–10 mm Hg, with effects amplified when combined with weight loss or sodium restriction.

Adopt the DASH diet by prioritizing fruits, vegetables, low-fat dairy, and whole grains while limiting saturated fats and sugars. This approach is clinically proven to lower blood pressure significantly, often matching the effectiveness of standard blood pressure medications, especially if you also manage your weight and sodium intake.

Restricting daily sodium intake to approximately 2 grams (5 grams of salt) reduces systolic blood pressure by approximately 7 mm Hg in hypertensive individuals.

Limit your daily sodium intake to about 2 grams (roughly one teaspoon of salt). Focus on avoiding processed and restaurant foods, which are the main sources of sodium, and use natural ingredients and herbs for flavoring. This single change can lower blood pressure by an amount comparable to taking a blood pressure medication.

Regular aerobic exercise of at least 150 minutes per week reduces systolic blood pressure by 4–7 mm Hg and diastolic blood pressure by 3–4 mm Hg.

Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, spread over 5-7 days. This could be brisk walking, cycling, or swimming. This amount of exercise can lower your blood pressure by an amount similar to taking a blood pressure medication. If you have uncontrolled high blood pressure, avoid high-intensity exercise until it is managed.

Sustained weight loss of at least 5% is recommended for individuals with overweight or obesity at moderate atherosclerotic cardiovascular disease (ASCVD) risk to reduce cardiometabolic risk factors and delay type 2 diabetes onset.

If you are at moderate cardiovascular risk, aim to lose just 5% of your body weight through a daily calorie deficit of 500-750 calories and 150 minutes of weekly exercise. This modest loss is scientifically proven to significantly lower your blood pressure, improve cholesterol, and drastically reduce your risk of developing type 2 diabetes.

Treatment with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) or GLP-1/GIP co-agonists (tirzepatide) is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce weight and cardiovascular risk factors.

If you have overweight or obesity and are at moderate or high cardiovascular risk, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are recommended treatments that significantly reduce weight and cardiovascular risk factors, often more effectively than lifestyle changes alone.

Semaglutide, a GLP-1 receptor agonist, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation.

Semaglutide is a prescription medication for T2DM and obesity that works by mimicking a gut hormone to regulate blood sugar, reduce appetite, and slow digestion. It is available as a weekly injection or a daily pill. Clinical trials show significant weight loss (4-15%) and improved blood sugar control (HbA1c reduction of 1.0-1.8%). Common side effects include nausea, which often improves over time. It is recommended for patients with cardiovascular risk.

Semaglutide (2.4 mg weekly) induces significant weight loss (approx. 14.9%) in adults with obesity, superior to Liraglutide (3 mg daily) and placebo.

Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing nearly 15% weight loss in clinical trials. It works by targeting brain pathways that control appetite. While it requires weekly injections, its efficacy is superior to older daily GLP-1 medications.

Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 11% in diabetics) and superior weight reduction compared to Semaglutide 1mg in patients with type 2 diabetes.

Tirzepatide is a weekly injection for type 2 diabetes that also causes significant weight loss (up to 11% in trials). It works by mimicking two gut hormones (GIP and GLP-1). It has been shown to reduce weight more than Semaglutide 1mg in diabetic patients.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle modification, produces clinically significant and sustained mean body weight reductions of 14–16% in adults without type 2 diabetes and 9.6% in adults with type 2 diabetes.

If you have obesity or overweight with a related health issue (like high blood pressure or diabetes) and lifestyle changes alone haven't worked, talk to your doctor about semaglutide 2.4 mg. It is a once-weekly injection taken alongside a healthy diet and exercise. It is not a substitute for lifestyle changes but helps overcome the body's natural tendency to regain weight. Be aware of potential side effects and that the dose starts low and increases gradually to help your body adjust.